Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 1
1975 2
1976 1
1978 2
1979 1
1980 1
1982 2
1983 2
1984 7
1985 3
1986 12
1987 4
1988 3
1989 12
1990 13
1991 15
1992 11
1993 11
1994 9
1995 8
1996 10
1997 18
1998 14
1999 16
2000 18
2001 8
2002 22
2003 13
2004 14
2005 25
2006 31
2007 32
2008 26
2009 33
2010 31
2011 40
2012 38
2013 49
2014 44
2015 56
2016 48
2017 52
2018 40
2019 35
2020 59
2021 62
2022 59
2023 44
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

961 results

Results by year

Filters applied: . Clear all
Page 1
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A. Tefferi A. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. Am J Hematol. 2021. PMID: 33197049 Free article. Review.
Presence of JAK2, CALR, or MPL mutation, expected in around 90% of the patients, is supportive but not essential for diagnosis; these mutations are also prevalent in the closely related MPNs, namely polycythemia vera (PV) and essential thrombocythemia (ET). The 2016 …
Presence of JAK2, CALR, or MPL mutation, expected in around 90% of the patients, is supportive but not essential for diagnosis; these mutati …
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
MUTATIONS: SRSF2, ASXL1, and U2AF1-Q157 mutations predict inferior survival in PMF; RAS/CBL mutations predict resistance to ruxolitinib therapy. ...RISK STRATIFICATION: Contemporary prognostic systems include GIPSS (genetically-inspired prognostic scoring …
MUTATIONS: SRSF2, ASXL1, and U2AF1-Q157 mutations predict inferior survival in PMF; RAS/CBL mutations predict resistance to ru …
Current management strategies for polycythemia vera and essential thrombocythemia.
Guglielmelli P, Vannucchi AM. Guglielmelli P, et al. Blood Rev. 2020 Jul;42:100714. doi: 10.1016/j.blre.2020.100714. Epub 2020 Jun 3. Blood Rev. 2020. PMID: 32546373 Review.
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of cardiovascular events, a varying burden of symptoms, and an intrinsic risk of evolution to secondary forms of myelofibrosis and acute leukem …
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of …
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.
Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Barosi G, et al. Blood. 2013 Jun 6;121(23):4778-81. doi: 10.1182/blood-2013-01-478891. Epub 2013 Apr 16. Blood. 2013. PMID: 23591792 Free PMC article.
Standardized response criteria to interpret and compare clinical trials are needed for approval of new therapeutic agents by regulatory agencies. The European LeukemiaNet (ELN) response criteria for essential thrombocythemia (ET) and polycythemia vera (PV) issued in …
Standardized response criteria to interpret and compare clinical trials are needed for approval of new therapeutic agents by regulatory agen …
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM. Passamonti F, et al. Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31. Leukemia. 2017. PMID: 28561069
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now on referred to as secondary myelofibrosis (SMF). No specific tools have been defined for risk …
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with variable risk of evolution int …
Myeloproliferative Neoplasms with Monocytosis.
Morsia E, Gangat N. Morsia E, et al. Curr Hematol Malig Rep. 2022 Feb;17(1):46-51. doi: 10.1007/s11899-021-00660-2. Epub 2021 Nov 13. Curr Hematol Malig Rep. 2022. PMID: 34773576 Review.
PURPOSE OF REVIEW: Myeloproliferative neoplasms (MPN) are a heterogeneous group of hematopoietic stem cell neoplasms comprising of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) that share driver mutations (JAK2/CALR/MPL) res …
PURPOSE OF REVIEW: Myeloproliferative neoplasms (MPN) are a heterogeneous group of hematopoietic stem cell neoplasms comprising of polycythe …
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Emanuel RM, et al. J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15. J Clin Oncol. 2012. PMID: 23071245 Free PMC article.
PATIENTS AND METHODS: The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. ...RESULTS: MPN-SAF TSS was calculable for 1,40 …
PATIENTS AND METHODS: The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the …
Approach to MPN Symptom Assessment.
Geyer H, Mesa RA. Geyer H, et al. Curr Hematol Malig Rep. 2017 Oct;12(5):381-388. doi: 10.1007/s11899-017-0399-5. Curr Hematol Malig Rep. 2017. PMID: 28942516 Free PMC article. Review.
RECENT FINDINGS: Significant heterogeneity exists both within and between MPN subtypes. Surrogates of disease burden such as risk scores and MPN chronicity often fail to correlate with symptomatic burden. ...
RECENT FINDINGS: Significant heterogeneity exists both within and between MPN subtypes. Surrogates of disease burden such as risk scores …
Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
Goulart H, Mascarenhas J, Tremblay D. Goulart H, et al. Ann Hematol. 2022 May;101(5):935-951. doi: 10.1007/s00277-022-04826-7. Epub 2022 Mar 28. Ann Hematol. 2022. PMID: 35344066 Review.
Thrombotic events are a distinctive feature of the myeloproliferative neoplasms (MPNs) polycythemia vera (PV) and essential thrombocythemia (ET). Patients with these MPNs may also experience a poor quality of life secondary to symptom burden, as well as progression …
Thrombotic events are a distinctive feature of the myeloproliferative neoplasms (MPNs) polycythemia vera (PV) and essential thromb …
Prognostic models in the myeloproliferative neoplasms.
Grinfeld J. Grinfeld J. Blood Rev. 2020 Jul;42:100713. doi: 10.1016/j.blre.2020.100713. Epub 2020 May 30. Blood Rev. 2020. PMID: 32532453 Review.
The management of myelofibrosis (MF) is predominantly supportive, with the use of JAK2 inhibitors or allogeneic stem cell transplantation reserved for patients predicted to have poor overall survival. Identification of these patients is aided by a number of prognostic s …
The management of myelofibrosis (MF) is predominantly supportive, with the use of JAK2 inhibitors or allogeneic stem cell transplantation re …
961 results